¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"TATA Box Binding Protein-Like Proteins"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • iron binding protein
    ö°áÇմܹéÁú
  • iron-binding capacity
    ö°áÇÕ´É
  • ligand binding site
    ¸®°£µå°áÇÕºÎÀ§
  • olfactory binding protein
    Èİ¢°áÇմܹéÁú
  • orthodontic binding wire
    ±³Á¤¿ë¹­±âö»ç, ±³Á¤¿ë°áÂû¼±
  • protein binding
    ´Ü¹éÁú°áÇÕ
  • receptor binding
    ¼ö¿ëü°áÇÕ
  • sex hormone-binding globulin
    ¼ºÈ£¸£¸ó°áÇձ۷κҸ°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • corticosteroid-binding globulin
    ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å°áÇձ۷κҸ°
  • cortisol-binding globulin
    ÄÚ¸£Æ¼¼Ö°áÇÕ±Û·Îºí¸°
  • iron-binding capacity
    ö°áÇÕ´É
  • gonadal steroid-binding globulin
    »ý½Ä»ù½ºÅ×·ÎÀ̵å°áÇձ۷κҸ°
  • sex hormone-binding globulin
    ¼ºÈ£¸£¸ó°áÇÕ±Û·Îºí¸°
  • testosterone-binding globulin
    Å×½ºÅ佺Å׷аáÇձ۷κҸ°
  • thyroxine-binding globulin
    Ƽ·Ï½Å°áÇÕ±Û·Îºí¸°
  • iron binding protein
    ö°áÇմܹéÁú
  • olfactory binding protein
    Èİ¢°áÇմܹé
  • orthodontic binding wire
    ±³Á¤¿ë¹­±âö»ç, ±³Á¤¿ë°áÂû¼±
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Langmuir expression in drug-antibody binding
    ¾à¹°-Ç×ü °áÇÕ¿¡¼­ÀÇ ¶û¹¿¸£Ç¥Çö
  • TBG => thyroxine binding globulin
    ŸÀ̷ϽаáÇÕ ±Û·ÎºÎ¸°
  • TBPA => thyroxine binding prealbumin
    ŸÀ̷ϽŰáÇÕÀü¾ËºÎ¹Î
  • TIBC => total iron binding capacity
    ÃÑö°áÇÕ´É
  • UIBC => unsaturated iron binding capacity
    ºÒÆ÷ȭö°áÇÕ´É
  • actin-binding protein
    ¾×ƾ °áÇմܹé(¡­Ì¿ùêÓ±ÛÜ)
  • androgen- binding protein
    ¸¸¼ºÈ£¸£¸ó °áÇմܹé
  • antibody binding site
    Ç×ü°áÇÕºÎÀ§
  • antibody, complement binding
    º¸Ã¼°áÇÕÇ×ü
  • antigen binding capacity
    Ç׿ø°áÇÕ´É(¡­Ì¿ùêÒö).
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen binding site
    Ç׿ø°áÇÕºÎÀ§
  • human zona binding assay
    »ç¶÷Á¤ÀÚ Åõ¸í´ëºÎÂø°Ë»ç
  • plasma protein binding
    Ç÷Àå´Ü¹é°áÇÕ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • actin-binding protein
    ¾×ƾ °áÇմܹé(¡­Ì¿ùêÓ±ÛÜ)
  • androgen- binding protein
    ¸¸¼ºÈ£¸£¸ó °áÇմܹé
  • antibody binding site
    Ç×ü°áÇÕºÎÀ§
  • antibody, complement binding
    º¸Ã¼°áÇÕÇ×ü
  • antigen binding capacity
    Ç׿ø°áÇÕ´É(¡­Ì¿ùêÒö).
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen binding site
    Ç׿ø°áÇÕºÎÀ§
  • binding
    °áÇÕ(Ì¿ùê)
  • binding
    ¹­À½, °áÇÕ.
  • binding activity
    °áÇÕȰ¼º(Ì¿ùêüÀàõ).
  • binding activity
    ¸é¿ª°áÇÕȰ¼º(Ì¿ùêüÀàõ).
  • binding affinity
    °áÇÕģȭ¼º(Ì¿ùêöÑûúàõ)
  • binding displacement analysis
    °áÇÕº¯À§ºÐ¼®(Ì¿ùêܨêÈÝÂà°).
  • binding energy
    °áÇÕ¿¡³ÊÁö
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • microtubule-associated proteins
    ¹Ì¼Ò°ü ¿¬°ü´Ü¹éÁú(Ú°á³Î·æáμӱÛÜòõ)
  • nonbasic chromosomal proteins
    ºñ¿°±â¼º ¿°»öü´Ü¹éÁú(Þªç¤Ðñàõæøßäô÷Ó±ÛÜòõ)
  • nonhistone chromosomal proteins
    ºñ(Þª)È÷½ºÅæ ¿°»öü(æøßäô÷)´Ü¹éÁú(Ó±ÛÜòõ)
  • plasma proteins
    Ç÷Àå ´Ü¹éÁú(úìíìÓ±ÛÜòõ)
  • serum proteins
    Ç÷û ´Ü¹éÁú(úìôèÓ±ÛÜòõ)
  • split proteins
    ºÐ¸® ´Ü¹éÁú(ÝÂ×îÓ±ÛÜòõ)
  • stress proteins
    ½ºÆ®·¹½º ´Ü¹éÁú(Ó±ÛÜòõ)
  • surface membrane proteins
    Ç¥¸é¸·´Ü¹éÁú (øúØüدӱÛÜòõ)
  • tau proteins
    Ÿ¿ì ´Ü¹éÁú (Ó±ÛÜòõ)
  • whey proteins
    À¯Àå(êáíì) ´Ü¹éÁú(Ó±ÛÜòõ)
  • androgen-binding protein
    ¾Èµå·ÎÀü°áÇÕ(Ì¿ùê) ´Ü¹éÁú(Ó±ÛÜòõ)
  • antibody binding fraction
    Ç×ü°áÇÕºÐȹ (ù÷ô÷Ì¿ùêÝÂüò)
  • antigen binding capacity
    Ç׿ø °áÇÕ´É(ù÷ê«Ì¿ùêÒö)
  • antigen binding site
    Ç׿ø°áÇÕ(ù÷ê«Ì¿ùê)ÀÚ¸®
  • antigen-binding fragment
    Ç׿ø°áÇÕ(ù÷ê«Ì¿ùê) Á¶°¢
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TBG beta-thromboglobulin; testosterone-binding globulin; thyroglobulin; thyroid-binding globulin; thyrox...
PVM pneumonia virus of mice; proteins, vitamins, and minerals
RPSP reference preparation for serum proteins
CAAX [box] protein segment in which C is cysteine, A is usually but not always an aliphatic amino acid, and X i...
EVB electronic view box; esophageal variceal bleeding
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
GBF G box binding factor
G proteins reglatory proteins
TATA Tumor-associated transplantation antigen
KRAB Kr uppel-associated box
PAX Paired box
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • ligand receptor binding
    ¸®°£µå ¼ö¿ë±â °áÇÕ
  • penicillin binding protein
    Æä´Ï½Ç¸° °áÇÕ ´Ü¹éÁú
  • plasma protein binding
    Ç÷Àå ´Ü¹é °áÇÕ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
CCAAT box <molecular biology> Consensus sequence for RNA polymerase, found at about 80 bases relative to the transcription start site. Less well conserved than the TATA box.
(18 Nov 1997)
Pribnow box <molecular biology> A region of DNA to which RNA polymerase binds before initiating the transcription of DNA into RNA.
The nucleotide at which transcription starts is designated +1 and nucleotides are numbered from this with negative numbers indicating upstream nucleotides and positive downstream nucleotides.
most bacterial promoters contain two consensus sequences that seem to be essential for the binding of the polymerase. The first, the Pribnow box, is at about 10 and has the consensus sequence 5' TATAAT 3'. The second, the 35 sequence, is centred about 35 and has the consensus sequence 5' TTGACA 3'.
most factors that regulate gene transcription do so by binding at or near the promoter and affecting the initiation of transcription. Much less is known about eukaryote promoters, each of the three RNA polymerases has a different promoter.
RNA polymerase I recognises a single promoter for the precursor of rRNA.
RNA polymerase II, that transcribes all genes coding for polypeptides, recognises many thousands of promoters. most have the Goldberg Hogness or TATA box that is centred around position 25 and has the consensus sequence 5' TATAAAA 3'. Several promoters have a CAAT box around 90 with the consensus sequence 5' GGCCAATCT 3'. There is increasing evidence that all promoters for housekeeping genes contain multiple copies of a GC rich element that includes the sequence 5' GGGCGG 3'. Transcription by polymerase II is also affected by more distant elements known as enhancers.
RNA polymerase III synthesises 5s ribosomal RNA, all tRNAs and a number of small RNAs. The promoter for RNA polymerase III is located within the gene either as a single sequence, as in the 5s RNA gene or as two blocks, as in all tRNA genes.
(13 Nov 1997)
Hogness box <molecular biology> A consensus sequence found in the promoter region of most genes transcribed by eukaryotic RNA polymerase II. Found about 25 nucleotides before the site of initiation of transcription and has the consensus sequence: 5' TATAAAA 3'. This sequence seems to be important in determining accurately the position at which transcription is initiated.
(18 Nov 1997)
Pu box <molecular biology> Purine rich sequence recognised by the product of the Sp 1 oncogene.
(18 Nov 1997)
snuff-box See: anatomical snuffbox.
(05 Mar 2000)
DEAD box helicase <enzyme> Family of ATP dependent DNA or RNA helicases with a 4 amino acid consensus, D E A D, that resembles an ATP binding site.
Examples, p68, a human nuclear protein involved in cell growth, vasa, a Drosophila protein required for specification of posterior embryonic structures.
(18 Nov 1997)
androgen binding protein A protein secreted by testicular Sertoli cells along with inhibin and mullerian inhibiting substance. Androgen binding protein probably maintains a high concentration of androgen in the seminiferous tubules.
(05 Mar 2000)
antigen-binding site <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope).
Also used of the site on a ligand molecule to which a cell surface receptor binds.
(18 Nov 1997)
binding <biochemistry, chemistry, molecular biology> The adherence of molecules to one another, for example, enzymes to substrates, antibodies to antigens, DNA strands to their complementary strands.
Binding occurs because the shape and chemical natures of parts of the molecules surfaces are complementary. A common metaphor is the "lock-and-key," used to describe how enzymes fit around their substrate.
(14 Nov 1997)
binding constant <chemistry> Reciprocal of dissociation constant. A measure of the extent of a reversible association between two molecular species at equilibrium.
(18 Nov 1997)
binding energy <chemistry, radiobiology> The binding energy of a nucleus is the minimum energy required to dissociate it into its component neutrons and protons. Neutron or proton binding energies are those required to remove a neutron or proton, respectively, from a nucleus. Electron binding energy is that required to remove an electron from an atom or a molecule.
(16 Dec 1997)
binding sites The reactive parts of a macromolecule that directly participate in its specific combination with another molecule.
(12 Dec 1998)
binding sites, antibody Local surface sites on antibodies which react with antigen determinant sites on antigens. They are formed from parts of the variable regions of the fab fragment of the immunoglobulin.
(12 Dec 1998)
calcium-binding protein <biochemistry> There are two main groups of calcium binding proteins, those that are similar to calmodulin and are called EF hand proteins and those that bind calcium and phospholipid (e.g. Lipocortin) and that have been grouped under the generic name of annexins.
Many other proteins will bind calcium, although the binding site usually has considerable homology with the calcium-binding domains of calmodulin. They can act as transport proteins, regulator proteins or activator proteins.
There is also a vitamin D-dependent variant which is a protein that plays a fundamental role in the vitamin d mediated transport of calcium in reptiles, amphibians, birds and mammals. It is found in the intestine, kidneys, egg shell gland, brain, and possibly other organs. Its molecular weight is species dependent.
(12 May 2002)
cap binding protein <molecular biology, protein> Protein (24 kD) with affinity for cap structure at 5' end of mRNA that probably assists, together with other initiation factors, in binding the mRNA to the 40S ribosomal subunit. Translation of mRNA in vitro is faster if it has a cap binding protein.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ballot box
    ÅõÇ¥ÇÔ
  • black box
    ÀüÀÚÀåÄ¡
  • box
    »óÀÚ;ȸ¾ç¸ñ;»óÀÚ¸ð¾çÀǰÍ;¼±À»µÎ¸¥±â»ç;»óÀÚ¿¡³Ö´Ù;µû±Í;µû±Í¸¦°¥±â´Ù
  • box kite
    »óÀÚ ¸ð¾çÀÇ ¿¬(Áַαâ»ó °üÃø¿ë)
  • box kite
    »óÀÚ¸ð¾çÀÇ¿¬
  • box office
    ¸ÅÇ¥¼Ò
  • box seat
    (±Ø µûÀ§ÀÇ)°£¸·Àº Á¼®;Ưº° Á¼®
  • box seat
    °£¸·ÀºÁ¼®;Ưº°Á¼®
  • box supper
    box lunch¸¦ ÆÈ¾Æ ±â¸§À» ¸ðÀ¸´Â ÀÚ¼± ´Üü ±³È¸°¡ ÁÖÃÖÇÏ´Â ÆÄƼ
  • box supper
    ±â±ÝÀ»¸ðÀ¸´ÂÀÚ¼±´Üü;±³È¸°¡ ÁÖÃÖÇÏ´Â ÆÄƼ
  • call box
    (°æÂû ¿¬¶ô.È­Àç ½Å°í¿ë)ºñ»óÀüÈ­;°øÁßÀüÈ­¹Ú½º
  • cartridge box
    ź¾à »óÀÚ
  • coach box
    ¸¶ºÎ¼®
  • coal-box
    ¼®Åº Åë;½¡ ±×¸©;(Á¦ 1Â÷ ´ëÀü ¶§ÀÇ)µ¶ÀϱºÀÇ Èæ¿¬ ÆøÅº
  • coin box
    (°øÁßÀüÈ­.ÀÚµ¿ÆÇ¸Å±â µîÀÇ)µ¿ÀüÅë;°øÁß ÀüÈ­
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á